# US 2021/0230166 A1 · 4-imidazopyridazin-1-yl-benzamides as btk inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230166 A1
- Document ID: US20210230166A1
- Status: Published application
- Kind: A1
- Application number: 17/142,202
- Filed: 2021-01-05
- Published: 2021-07-29
- Earliest claimed: 2011-07-19
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme B.V.
- Inventors: Tjeerd A. Barf; Christiaan Gerardus Johannes Maria Jans; Adrianus Petrus Antonius de Man; Arthur A. Oubrie; Hans C.A. Raaijmakers; Johannes Bernardus Maria Rewinkel; Jan Gerard Sterrenburg; Jacobus C.H.M. Wijkmans
- Web page: https://patentgrep.com/patent/US20210230166A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating acute lymphocytic leukemia (ALL) in a human subject, the method comprising administering to the human subject a compound that is
(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound is present in a pharmaceutical composition.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable auxiliaries.

### Claim 5 (depends on 3)

The method of claim 3, wherein the pharmaceutical composition is administered to the human subject by oral administration.

### Claim 6 (depends on 4)

The method of claim 4, wherein the pharmaceutical composition is administered to the human subject by oral administration.

### Claim 7 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is a tablet.

### Claim 8 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is a tablet.

### Claim 9 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is a capsule.

### Claim 10 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is a capsule.

### Claim 11 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is a suspension.

### Claim 12 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is a suspension.

### Claim 13 (depends on 2)

The method of claim 2, wherein the compound is administered to the human subject in an amount of 0.0001-25 mg per kg body weight.

### Claim 14 (depends on 2)

The method of claim 2, wherein (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject.

### Claim 15 (depends on 2)

The method of claim 2, wherein a pharmaceutically acceptable salt of (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject.
